POLYPID
NASDAQ: PYPD (PolyPid Ltd.)
Kemas kini terakhir: 1 jam lalu4.84
0.11 (2.33%)
| Penutupan Terdahulu | 4.73 |
| Buka | 4.59 |
| Jumlah Dagangan | 264,951 |
| Purata Dagangan (3B) | 231,019 |
| Modal Pasaran | 92,802,544 |
| Harga / Buku (P/B) | 10.42 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -4.24 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10,265.12% |
| Nisbah Semasa (MRQ) | 0.710 |
| Aliran Tunai Operasi (OCF TTM) | -21.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -12.03 M |
| Pulangan Atas Aset (ROA TTM) | -86.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -853.05% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | PolyPid Ltd. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -1.00 |
|
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 25.65% |
| % Dimiliki oleh Institusi | 49.51% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Symmetry Peak Management Llc | 31 Mar 2026 | 87,193 |
| Lumbard & Kellner, Llc | 31 Mar 2026 | 38,200 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |